GW Pharmaceuticals Plc (GWP):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:GW Pharmaceuticals Plc (GWP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3453
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
GW Pharmaceuticals Plc (GW Pharmaceuticals) is a biopharmaceutical company that discovers, develops and commercializes novel therapeutics from its proprietary cannabinoid product platform. The company’s commercialized product, Sativex is a plant-derived cannabinoid prescription drug, for the treatment of spasticity due to multiple sclerosis. It sells and distributes the product through strategic collaborations with other pharmaceutical companies. GW Pharmaceuticals is also developing products for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis, infantile spasms, epilepsy syndrome, glioma, schizophrenia, autism among others. The company has subsidiaries in Australia, the US, England and Wales, and Guernsey. GW Pharmaceuticals is headquartered in Cambridgeshire, the UK.

GW Pharmaceuticals Plc (GWP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
GW Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 10
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 12
Private Equity 12
Mentor Capital Invests USD1 Million in GW Pharma 12
Partnerships 13
GW Pharma Enters into Research Agreement with New South Wales 13
GW Pharma Enters Into Distribution Agreement With Ipsen For Sativex 14
Equity Offering 15
GW Pharma Raises USD317.4 Million in Public Offering of Shares 15
GW Pharma Raises USD290 Million in Public Offering of American Depositary Shares 17
GW Pharma Completes Exercise of Underwriter’s Over Allotment Option for Public Offering of ADSs for USD206 Million 19
GW Pharma Raises USD126 Million in Public Offering of American Depositary Shares 21
GW Pharma Completes Public Offering Of American Depositary Shares For US$101 Million 23
GW Pharma Announces Partial Exercise Of Underwriter’s Option Of American Depository Shares For US$33 Million 25
Acquisition 27
GW Pharma May Sell Itself 27
GW Pharmaceuticals Plc – Key Competitors 28
GW Pharmaceuticals Plc – Key Employees 29
GW Pharmaceuticals Plc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Aug 07, 2018: GW Pharmaceuticals reports fiscal third quarter 2018 financial results and operational progress 31
May 08, 2018: GW Pharmaceuticals Announces Fiscal Second Quarter 2018 Financial Results 33
Feb 05, 2018: GW Pharmaceuticals Reports Q1 Fiscal 2018 Financial Results 34
Dec 04, 2017: GW Pharmaceuticals Reports Fiscal Fourth Quarter 2017 and Year-End Financial Results and Operational Progress 37
Aug 07, 2017: GW Pharmaceuticals Reports Fiscal Third Quarter 2017 Financial Results 39
May 09, 2017: GW Pharmaceuticals Reports Fiscal Second Quarter 2017 Financial Results and Operational Progress 41
Feb 07, 2017: GW Pharmaceuticals Reports First Quarter 2017 Financial Results and Operational Progress 43
Corporate Communications 44
Dec 21, 2017: GW Pharmaceuticals Announces the Appointment of Three New Independent Members to its Board of Directors 44
May 15, 2017: GW Pharmaceuticals Announces Research & Development Management Appointments 45
Mar 07, 2017: GW Pharmaceuticals Announces the Appointment of Scott Giacobello as Chief Financial Officer and Adam George as Managing Director – UK 46
Legal and Regulatory 47
Aug 02, 2018: Certara Software or Services supported 95% of the US FDA novel drug approvals in first half of 2018 47
Government and Public Interest 48
Feb 23, 2017: First Ever Cannabis-Based ETF to Include PharmaCyte Biotech, Abbott Laboratories, and GW Pharmaceuticals 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GW Pharmaceuticals Plc, Deals By Therapy Area, 2012 to YTD 2018 9
GW Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 10
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Mentor Capital Invests USD1 Million in GW Pharma 12
GW Pharma Enters into Research Agreement with New South Wales 13
GW Pharma Enters Into Distribution Agreement With Ipsen For Sativex 14
GW Pharma Raises USD317.4 Million in Public Offering of Shares 15
GW Pharma Raises USD290 Million in Public Offering of American Depositary Shares 17
GW Pharma Completes Exercise of Underwriter's Over Allotment Option for Public Offering of ADSs for USD206 Million 19
GW Pharma Raises USD126 Million in Public Offering of American Depositary Shares 21
GW Pharma Completes Public Offering Of American Depositary Shares For US$101 Million 23
GW Pharma Announces Partial Exercise Of Underwriter’s Option Of American Depository Shares For US$33 Million 25
GW Pharma May Sell Itself 27
GW Pharmaceuticals Plc, Key Competitors 28
GW Pharmaceuticals Plc, Key Employees 29
GW Pharmaceuticals Plc, Other Locations 30
GW Pharmaceuticals Plc, Subsidiaries 30

List of Figures
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
GW Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[GW Pharmaceuticals Plc (GWP):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Span-America Medical Systems Inc (SPAN):企業の財務・戦略的SWOT分析
    Summary Span-America Medical Systems Inc (Span-America), a subsidiary of Savaria Corp, is a medical device company that designs and manufactures pressure management and patient positioning products. The company offers products such as surfaces, seat cushions, patient positioners, skin care products, …
  • Swissgrid AG:電力:M&Aディール及び事業提携情報
    Summary Swissgrid AG (Swissgrid) is a national grid company that operates, maintains, modernizes and expands the electricity transmission system in Switzerland. It conducts the import and export of electricity to maintain the utilization levels. The company also provides additional services, such as …
  • Sirius XM Holdings Inc.:戦略・SWOT・企業財務分析
    Sirius XM Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Sirius XM Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Messer Cutting Systems GmbH:企業の戦略的SWOT分析
    Messer Cutting Systems GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Deutsche Bank AG:企業のM&A・事業提携・投資動向
    Deutsche Bank AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Deutsche Bank AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Beijing SL Pharmaceutical Co Ltd (002038)-製薬・医療分野:企業M&A・提携分析
    Summary Beijing SL Pharmaceutical Co Ltd (SL Pharma), formerly Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd is a bio-pharmaceutical company that develops and markets gene engineering drugs. The company offers products in the field of oncology, organ transplantation, wound management, cardivascular, …
  • Price Forbes & Partners Ltd.:企業の戦略・SWOT・財務情報
    Price Forbes & Partners Ltd. - Strategy, SWOT and Corporate Finance Report Summary Price Forbes & Partners Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • China Mobile Limited:企業の戦略・SWOT・財務情報
    China Mobile Limited - Strategy, SWOT and Corporate Finance Report Summary China Mobile Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Semtech Corp (SMTC):企業の財務・戦略的SWOT分析
    Summary Semtech Corp (Semtech) operates as a supplier of analog and mixed-signal semiconductor products. The company provides products such as isolated power switches, UHD-SDI gearbox, wireless charging ICs, battery chargers, cable drivers, capacitive touch controllers, charge pump and current sink …
  • Biogen Inc (BIIB)-製薬・医療分野:企業M&A・提携分析
    Summary Biogen Inc (Biogen) is a global biotechnology company that manufactures and markets drugs for the treatment of neurodegenerative diseases and rare and autoimmune disorders. Its marketed products include Avonex (interferon beta-1a), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Zinbry …
  • BESIX Group SA:企業の戦略的SWOT分析
    BESIX Group SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Ghent University-製薬・医療分野:企業M&A・提携分析
    Summary Ghent University (Ghent) is an educational institution that provides research-based educational programmes and services. The university provides educational services such as international courses, preparatory language courses, programmes for exchange students and language courses, among othe …
  • Antibe Therapeutics Inc (ATE)-製薬・医療分野:企業M&A・提携分析
    Summary Antibe Therapeutics Inc (Antibe) is a biotechnology company that designs and develops drug candidates for chronic pain and inflammation; and regenerative medicine. The company discovers and commercialize novel drugs, biologics and medical devices. It offers lead compound ATB-346, a naproxen …
  • Evoke Pharma Inc (EVOK):企業の財務・戦略的SWOT分析
    Summary Evoke Pharma Inc (Evoke Pharma) is a pharmaceutical company that develops drugs to treat gastrointestinal diseases. The company offers Gimoti that provides predictable absorption and symptom relief during a flare regardless of gastric emptying delays and vomiting. It also offers solutions fo …
  • Telecom Argentina S.A.:企業の戦略・SWOT・財務情報
    Telecom Argentina S.A. - Strategy, SWOT and Corporate Finance Report Summary Telecom Argentina S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Specialist Investment Properties PLC:企業の戦略・SWOT・財務情報
    Specialist Investment Properties PLC - Strategy, SWOT and Corporate Finance Report Summary Specialist Investment Properties PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Bechtel Corporation:企業の戦略的SWOT分析
    Bechtel Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • KeyCorp:企業の戦略・SWOT・財務情報
    KeyCorp - Strategy, SWOT and Corporate Finance Report Summary KeyCorp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Dechra Pharmaceuticals Plc (DPH):企業の財務・戦略的SWOT分析
    Summary Dechra Pharmaceuticals Plc (Dechra) is a manufacturer and distributor of veterinary pharmaceutical products. The company's product portfolio includes vetoryl, felimazole, thyforon, malaseb, canaural, isaderm, cardisure, comfortan, libromide, somulose, vetoryl, rapidexon, octacillin, domidine …
  • Dongfang Electric Corporation Ltd (1072)-エネルギー分野:企業M&A・提携分析
    Summary Dongfang Electric Corporation Ltd (DEC) a subsidiary of Dongfang Electric Corporation, is a power equipment and services company. It designs, manufactures, and sells power generation equipment, including turbines for hydro, thermal, and nuclear power generation, wind turbine generator sets, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆